

MRPL40 Antibody (C-term) Blocking Peptide Synthetic peptide

Catalog # BP18646b

Specification

MRPL40 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

<u>Q9NQ50</u>

MRPL40 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 64976

Other Names

39S ribosomal protein L40, mitochondrial, L40mt, MRP-L40, Nuclear localization signal-containing protein deleted in velocardiofacial syndrome, Up-regulated in metastasis, MRPL40, NLVCF, URIM

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MRPL40 Antibody (C-term) Blocking Peptide - Protein Information

Name MRPL40

Synonyms NLVCF, URIM

Cellular Location Mitochondrion

Tissue Location Ubiquitous..

MRPL40 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

MRPL40 Antibody (C-term) Blocking Peptide - Images

MRPL40 Antibody (C-term) Blocking Peptide - Background



Mammalian mitochondrial ribosomal proteins are encoded bynuclear genes and help in protein synthesis within themitochondrion. Mitochondrial ribosomes (mitoribosomes) consist of asmall 28S subunit and a large 39S subunit. They have an estimated75% protein to rRNA composition compared to prokaryotic ribosomes, where this ratio is reversed. Another difference between mammalianmitoribosomes and prokaryotic ribosomes is that the latter containa 5S rRNA. Among different species, the proteins comprising themitoribosome differ greatly in sequence, and sometimes inbiochemical properties, which prevents easy recognition by sequencehomology. This gene encodes a 39S subunit protein. Deletions inthis gene may contribute to the etiology of velo-cardio-facialsyndrome and DiGeorge syndrome.

MRPL40 Antibody (C-term) Blocking Peptide - References

Collins, J.E., et al. Genome Biol. 5 (10), R84 (2004) :Zhang, Z., et al. Genomics 81(5):468-480(2003)Kenmochi, N., et al. Genomics 77 (1-2), 65-70 (2001) :Hildebrandt, T., et al. Anticancer Res. 19 (1A), 525-530 (1999) :Goldschmidt-Reisin, S., et al. J. Biol. Chem. 273(52):34828-34836(1998)